Friday, April 15, 2022 2:26:40 PM
In either case it has been presumed that if some mechanism could be discovered that would clear those waste proteins from neurons, the Alzheimer’s problem would be solved. In fact, that might be the case — if such a waste-clearing drug could ever be discovered.
So far, the approach has been to tweak the immune system to make molecules that will latch on to the waste proteins and thereby digest or transport them out of the cell. “Passive immunization with monoclonal antibodies (mAbs) may be able to clear toxic amyloid-ß species either directly or through microglia or complement activation, thereby halting the amyloid cascade and preventing neurodegeneration and cognitive and functional decline.”
https://pubmed.ncbi.nlm.nih.gov/24216217/
Wonderful idea. But, simply, it has never worked. Billions of dollars have been spent working up these monoclonal antibodies and testing them in either rodents or humans. In every case, consequential or disqualifying adverse events (“side effects”), with minimal therapeutic outcomes. It is abundantly clear that tweaking immunological processes fails, altogether.
But for most Alzheimer’s researchers there’s nothing else to try. Try, and try again, has been the continuing theme.
Except for Anavex Life Sciences Corp. Their approach is entirely different. Their drugs do not directly target beta-amyloid or tau wastes. Instead, they target, are ligands, of the unique sigma-1 receptor protein. When they attach (that’s what ligands do) the protein is said to be “activated” (or “agonized”). With this the protein is propitiously active, being able to control, modulate, or promote a diversity of “downstream” cellular processes; ones that don’t work well in the diseased state.
And, yes, one of those processes is “autophagy,” the cell’s housekeeping functions that grab onto, digest, and clear all of the many chemical wastes that are generated in, among others, neurons. And, yes, some of those wastes may, indeed, be beta-amyloids or tau tangles.
But, better, blarcamesine-activation of the sigma-1 receptor protein causes all sorts of downstream processes to work normally. One of the most important of these is the proper folding of enzyme proteins, making enzymes that are fully functional. With those, fewer wastes are formed, and those that do appear can be enzymatically destroyed or transported out of the cell.
That’s the deal of Anavex and blarcamesine; a unique, safe, and effective mechanism of action (MOA) unlike any other. At the top or start of all sorts of reaction cascades, it puts those in functional order; exactly what’s missing in the various CNS pathologies.
All of this is brand new. Medical researchers never heard of the sigma-1 receptor protein until they saw it in the Anavex research papers. It didn’t fit anything they knew of. It was utterly “unproven science,” with magical, too-good-to-be-true clinical results in lab rodents, utilizing an un-described, very questionable MOA. No medical professional wants to put his career on the line with such murky stuff.
Won’t it be interesting to see how medical professionals react to the upcoming Phase 3 Alzheimer’s results. Like them or not, the Anavex MOA will be entirely validated; pointing to efficacies for all of the pathologies in the Anavex pipeline. New medical technology; altogether transformative. Not only will Parkinson’s and Alzheimer’s be treated with blarcamesine, it will soon be discovered that, even better, the drug will prevent them; prophylaxis.
Finally, a few years later, it will be discovered that blarcamesine is a useful, therapeutic anti-aging agent, slowing normal aging processes and inhibiting the onset of geriatric diseases and conditions; all of which are inhibited by blarcamesine’s ability to maintain or restore youthful cellular processes, with its unique activation of the sigma-1 receptor protein.
Recent AVXL News
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM